Citations

Clear

634 citation(s) found for "Hall, A".

Intrarenal modulation of NF-κB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis
Chade, Alejandro , Engel, Jason , Hall, Michael E. , Eirin, Alfonso , Bidwell, Gene L. , Chade, Alejandro R , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 16, 2021 | Volume: 321 | Issue: 4 | Pages: F411-F423

10.1152/ajprenal.00158.2021 | PMID 34396789 Get It

Chronic kidney disease (CKD) is a progressive disorder with high cardiovascular morbidity and mortality. This work supports the role of inflammatory cytokines of renal origin in renal-cardio pathophysiology in CKD and that the heart may be a target. Furthermore, it supports the feasibility of a new strategy in a translational fashion, using targeted inhibition of renal NF-κB signaling to offset the development of cardiac injury in CKD.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Nesic, Ksenija , Kondrashova, Olga , Hurley, Rachel M. , McGehee, Cordelia D. , Ho, Gwo‐Yaw , Lieschke, Elizabeth , Dall, Genevieve , Bound, Nirashaa , Shield‐Artin, Kristy , Musafer, Ashan, Chai, Zi Qing, Ghamsari, Mohammad Reza Eftekhariyan , Harrell, Maria I., Kee, Damien , Olesen, Inger, McNally, Orla , Study, Australian Ovarian Cancer, DeFazio, Anna , Bowtell, David D.L. , Swisher, Elizabeth M. , Weroha, S. John , Nones, Kátia , Waddell, Nicola , Wakefield, Matthew J. , Scott, Clare L. , Ho, Gwo-Yaw , Ghamsari, Mohammad Reza Eftekhariyan , Kee, Damien , Fazio, Anna de , Swisher, Elizabeth M , Nones, Katia , Waddell, Nicola , Kaufmann, Scott H , Dobrovic, Alexander , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Bowtell, David D , Vandenberg, Cassandra J. , Radke, Marc R. , Traficante, Nadia , Kaufmann, Scott H.

Mayo Clinic

Cancer Research | July 28, 2021 | Volume: 81 | Issue: 18 | Pages: 4709-4722

10.1158/0008-5472.can-21-0774 | PMID 34321239 Get It

Abstract In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. RAD51C promoter methylation (meRAD51C) is detected at similar frequencies to mutations, yet its effects on PARPi responses remain unresolved. In this study, three HGSC patient-derived xenograft (PDX) models with methylation at most or all examined CpG sites in the RAD51C promoter show responses to PARPi. Both complete and heterogeneous methylation patterns were associated with RAD51C gene silencing and homologous recombination deficiency (HRD). PDX models lost meRAD51C following treatment with PARPi rucaparib or niraparib, where a single unmethylated copy of RAD51C was sufficient to drive PARPi resistance. Genomic copy number profiling of one of the PDX models using SNP arrays revealed that this resistance was acquired independently in two genetically distinct lineages. In a cohort of 12 patients with RAD51C-methylated HGSC, various patterns of meRAD51C were associated with genomic “scarring,” indicative of HRD history, but exhibited no clear correlations with clinical outcome. Differences in methylation stability under treatment pressure were also observed between patients, where one HGSC was found to maintain meRAD51C after six lines of therapy (four platinum-based), whereas another HGSC sample was found to have heterozygous meRAD51C and elevated RAD51C gene expression (relative to homozygous meRAD51C controls) after only neoadjuvant chemotherapy. As meRAD51C loss in a single gene copy was sufficient to cause PARPi resistance in PDX, methylation zygosity should be carefully assessed in previously treated patients when considering PARPi therapy. Significance: Homozygous RAD51C methylation is a positive predictive biomarker for sensitivity to PARP inhibitors, whereas a single unmethylated gene copy is sufficient to confer resistance.
Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Hurley, Rachel M. , McGehee, Cordelia D. , Nesic, Ksenija , Weiskittel, Taylor M. , Kelly, Rebecca L. , Venkatachalam, Annapoorna , Hou, Xiaonan , Pathoulas, Nicholas M. , Meng, X. Wei, Kondrashova, Olga , Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Becker, Marc A., Southey, Melissa S, Harding, Thomas C., McNeish, Iain A. , Wagner, Jill M., Wakefield, Matthew J. , Scott, Clare L. , Hendrickson, Andrea E. Wahner , Karnitz, Larry M., Swisher, Elizabeth M. , Weroha, S. John , Lin, Kevin K. , Dobrovic, Alexander , Ross, Christian A, Haluska, Paul , Kaufmann, Scott H , McNeish, Iain A , Swisher, Elizabeth M , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Correia, Cristina , Radke, Marc R. , Wong, Ee Ming , Lin, Kevin , Roß, Christian , Li, Hu , Kaufmann, Scott H.

Mayo Clinic

NAR Cancer | July 10, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/narcan/zcab028 | PMID 34316715 Get It

Abstract Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous recombination (HR) deficiency and PARPi sensitivity. For this study, the PARPi-sensitive patient-derived ovarian cancer xenograft PH039, which lacks HR gene mutations but harbors RAD51C promoter methylation, was selected for PARPi resistance by cyclical niraparib treatment in vivo. PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Transcriptional profiling throughout the course of resistance development showed widespread pathway level changes along with a marked increase in RAD51C mRNA, which reflected loss of RAD51C promoter methylation. Analysis of ovarian cancer samples from the ARIEL2 Part 1 clinical trial of rucaparib monotherapy likewise indicated an association between loss of RAD51C methylation prior to on-study biopsy and limited response. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.
Abstract 266: MicroRNA Profiling Identifies Enrichment for Proteoglycan-Genes in Symptomatic Carotid Plaques
Adhikari, Neeta , Carlson, Marjorie, Loeffler, Darrell , Walek, Dinesha, Daniel, Jerry , Mackey, Aaron J. , Lawson, Mark, Lerman, Amir , Hall, Jennifer L.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 3, 2021 | Volume: 32 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.32.suppl_1.a266 Get It

MicroRNAs are a class of small non-coding RNAs that regulate gene expression by binding to discrete sites of genes and inhibiting translation. The objective of this study was to identify microRNAs and downstream enriched targets associated with symptomatic carotid plaques. Carotid plaque samples from patients were defined as symptomatic if they were associated with a prior ischemic stroke or transient ischemic attack, or as asymptomatic if there were no prior ischemic events. Digital microRNA profiling was performed on the NanoString nCounter analysis system (NanoString Technologies, Seattle, WA) on carotid plaques from symptomatic (n=6) and asymptomatic (n=6) patients. We used the BioConductor/R package "edgeR" to perform moderated-ANOVA testing for differences in gene abundance between groups, assuming a negative binomial distribution of gene counts, with Benjamini-Hochberg multiple hypothesis correction to control false discovery rate. Analysis revealed five microRNAs that were significantly up-regulated in the symptomatic cohort (see Table 1) including miR-16, which was confirmed by RTqPCR (p=0.02). Predicted downstream targets of miR-16 were enriched for proteoglycan related genes including hyaluronan synthase 2, perlecan and betaglycan. Additionally, RTqPCR demonstrated up-regulation of CathepsinB transcript in symptomatic patients (n=46-50 per cohort, p=0.02) while CathepsinL and heparanase transcripts were not significantly different. CathepsinL enzyme activity was also not significantly different (n=46-50 per cohort). Taken together, these findings may reveal novel proteoglycan mediated signaling pathways, mediated through miR-16, regulating the progression of carotid plaque formation.
Abstract 02: Association Between Hospital Volume of Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest and Survival to Hospital Discharge
Akintoye, Emmanuel , Ando, Tomo , Alade, Adedotun, Egbe, Alexander C. , Afonso, Luis , Adegbala, Oluwole Muyiwa , Briasoulis, Αlexandros

Mayo Clinic

Circulation | July 2, 2021 | Volume: 138 | Issue: Suppl_2 | Pages: No page available

10.1161/circ.138.suppl_2.02 Get It

Background: Prior studies have shown that hospital case volume is not associated with survival in patients with out-of-hospital cardiac arrest (OHCA). However, how case volume impact on survival for in-hospital cardiac arrest (IHCA) is unknown Methods: We queried the National Inpatient Sample (NIS) in the U.S. 2005-2011 to identify cases in which in-hospital CPR was performed for IHCA. Years > 2011 were excluded due to redesign of NIS that precludes case volume calculation. Restricted cubic spine was used to evaluate the association between hospital annual CPR volume and survival to hospital discharge. Further analysis was conducted with case volume in quartiles. Results: Across more than 1000 hospitals in NIS, we identified 137,466 cases (mean age 67, 45% female) of IHCA for which CPR was performed over the study period. Median [Q1, Q3] case volume was 68 [34, 100]. Compared to those in the 1 st quartile (q1) of case volume, hospitals in the 4 th quartile (q4) tends to have younger patients (mean=66 vs 68 yrs), higher comorbidities (median Elixhauser score=4 vs 3), large bed size (89 vs 37%), and in low income areas (37 vs 32%). After adjustment for patient and hospital factors, higher hospital case volume was inversely associated with lower rates of survival (Fig1). Risk-adjusted rates of survival from q1 through q4 were: 28.1%, 25.5%, 25.4% and 23.7%. We arrived at similar results when analysis was stratified by age, gender and hospital bed size (not shown) except that the difference across quartiles was more pronounced among small bed size hospitals (survival rate=27.4% in q1 vs 8.1% in q4). However, among those who survived to hospital discharge, nonroutine home discharge was higher among patients in q1 (73.9%) vs q4 (69.6%) Conclusion: Unlike OHCA, hospital case volume is inversely associated with survival to hospital discharge in patients undergoing CPR for IHCA. Hence, quality measures to reduce the incidence of CPR/IHCA have the potential to reduce in-hospital mortality
Genome-wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk among 62,370 Women
Kapoor, Pooja, Auer, Paul, Dennis, Joe, Wang, Qin , Bolla, Manjeet K. , Aronson, Kristan J. , Lee, Derrick , Cordina‐Duverger, Emilie, Mulot, Claire , Teras, Lauren R., Patel, Alpa V. , Hoppe, Reiner , Lo, Wing‐Yee, Brüning, Thomas , Hamann, Ute, Couch, Fergus, Ruddy, Kathryn J. , MacInnis, Robert J. , Wilkens, Lynne, Haiman, Christopher A. , Krüger, Ute , Wagner, Philippe , Vachon, Celine M. , Eliassen, Heather, Andrulis, Irene L. , Evans, D. Gareth , Ziogas, Argyrios, Orr, Nick , Linet, Martha S. , Prentice, Ross L. , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Evans, D Gareth , Maclnnis, Robert , Orr, Nick , Wang, Xiaoliang , Kapoor, Pooja, Dunning, Alison M. , Lush, Michael J. , Michailidou, Kyriaki , Murphy, Rachel A. , Brooks‐Wilson, Angela , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Dossus, Laure , Kaaks, Rudolf , Czene, Kamila , Gabrielson, Marike , Hall, Per N , Eriksson, Mikael , Jung, Audrey , Becher, Heiko , Couch, Fergus J. , Larson, Nicole, Olson, Janet E. , Giles, Graham G. , Southey, Melissa C. , Marchand, Loı̈c Le , Wilkens, Lynne R. , Olsson, Håkan , Augustinsson, Annelie , Scott, Christopher, Winham, Stacey J. , Vachon, Celine M. , Perou, Charles M. , Olshan, Andrew F. , Troester, Melissa A. , Hunter, David, Eliassen, A. Heather , Tamimi, Rulla M. , Brantley, Kristen D. , Figueroa, Jonine D. , Chanock, Stephen Jacob , Ahearn, Thomas U. , García‐Closas, Montserrat , Newman, William G. , Veen, Elke M. van , Howell, Anthony , Wolk, Alicja , Håkansson, Niclas , Anton‐Culver, Hoda , Jones, Michael E. , Schoemaker, Minouk J. , Swerdlow, Anthony J. , Kitahara, Cari M. , Milne, Roger L. , Kraft, Peter

Mayo Clinic

No container title available | July 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-532921/v2 Get It

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values<5x10-8 as genome-wide significant, and p-values<1x10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants.Results: None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values<1x105. The strongest evidence was found for rs4674019 (p-value=2.27x10-7), which showed genome-wide significant interaction (p-value=3.8x10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. Conclusions: In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT–breast cancer risk association.
Abstract 449: A standard operating procedure for the curation of gene fusions
Terraf, Panieh, Coard, Thomas, Ritter, Deborah , Tańska, Anna , Berlin, Aaron M., Lu, Anna, Williams, Heather , Lin, Wan‐Hsin , Danos, Arpad , Xu, Huiling , Xu, Xinjie , Ryland, Georgina L., Zhang, Liying , Rapisardo, Sarah, Rehder, Catherine , Pallavajjala, Aparna, Park, Nicole, Satgunaseelan, Laveniya , Liu, Jie , Stenzinger, Albrecht , Lee, Jennifer, Roy, Angshumoy , Raca, Gordana , Satgunaseelan, Laveniya , Wagner, Alex H. , Vlachos, Ioannis S. , Sonkin, Dmitriy , Kesserwan, Chimene A. , Sboner, Andrea , Reich, Christian , Horak, Peter , Zou, Ying , Cameron, Daniel , Törüner, Gökçe , Saliba, Jason , Ceccarelli, Michele , Liu, Xuelu, Lee, Kristy , Griffith, Obi L. , Freimuth, Robert R. , Baughn, Linda B. , Baudis, Michael , Li, Marilyn M

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 449-449

10.1158/1538-7445.am2021-449 Get It

Abstract Despite the well-established role of recurrent gene fusions as oncogenic drivers, current practices for characterizing and interpreting gene fusion events in clinical testing and in biomedical literature are inconsistent. From the conceptual definition of gene fusions to the salient elements that characterize these alterations, a lack of community-driven standards for the curation of gene fusions has resulted in a disparate landscape of fusion representations and supporting tools. Consequently, the evidence-based clinical evaluation of gene fusions requires extensive expert review for accurate interpretation of observed gene fusions with respect to putative evidence from biomedical literature. Furthermore, the lack of these standards inhibits the interoperability of tools, resources, and pipelines - impeding data sharing and downstream utility.To address these challenges, a cross-consortia initiative between the Variant Interpretation for Cancer Consortium and ClinGen was formed to develop a standard operating procedure (SOP) for the curation of gene fusions. The SOP is under development by an international and diverse set of experts in the representation, detection, and clinical interpretation of gene fusions. Participating stakeholders across academic, government, and industry sectors showcased challenges and solutions, and participated in community surveys and discussions to define and develop the SOP for this diverse class of alterations.An initial result of this effort was the precise molecular definition of genomic events and features constituting gene fusions. We distinguish these from similar but distinct classes of structural alterations through clinically-relevant examples. Next, we discuss our findings on community practices around the description and evaluation of gene fusions. We provide our recommendations for characterization and representation of gene fusions from these practices, and compare these recommendations to existing variant representation standards and formats (e.g. HGVS variant nomenclature). We also discuss the concurrent application of formats for standardized human- and machine-readable representations of gene fusion events.We conclude with discussion of the salient elements to enable rapid, scalable, and consistent evaluation of fusions curated from the biomedical literature. Recommendations are provided for the standardized capture of these elements to enable both intuitive and precise characterization of this diverse class of alterations in clinical reporting and literature. In summary, we provide a clinical-practice driven framework and nomenclature for gene fusions, including recommendations for human readability, computational precision, and data integrity within the SOP. This work is a substantial advancement towards standardized communication, investigation, and sharing of gene fusion data across clinical and research domains and specialties. Citation Format: Alex H. Wagner, Ioannis S. Vlachos, Dmitriy Sonkin, Panieh Terraf, Chimene Kesserwan, Andrea Sboner, Thomas Coard, Christian Reich, Deborah I. Ritter, Peter Horak, Ying S. Zou, Anna Tanska, Aaron M. Berlin, Anna Lu, Daniel Cameron, Heather E. Williams, Wan-Hsin Lin, Gokce Toruner, Arpad Danos, Jason Saliba, Huiling Xu, Xinjie Xu, Georgina Ryland, Michele Ceccarelli, Liying Zhang, Sarah Rapisardo, Catherine Rehder, Xuelu Liu, Aparna Pallavajjala, Nicole Park, Laveniya Satgunaseelan, Kristy Lee, Jie Liu, Obi Griffith, Robert R. Freimuth, Albrecht Stenzinger, Linda B. Baughn, Michael Baudis, Jennifer Lee, Marilyn Li, Angshumoy Roy, Gordana Raca. A standard operating procedure for the curation of gene fusions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 449.
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Montgomery, Jay R, Ryan, Margaret A. K. , Engler, Renata J.M. , Hoffman, Donna L. , McClenathan, Bruce , Collins, Limone, Loran, David , Hrncir, David, Herring, Kelsie, Platzer, Michael, Adams, Nehkonti , Sanou, Aliye Z, Hoffman, Donna, Platzer, Michael, Cooper, Leslie T.

Mayo Clinic

JAMA Cardiology | June 29, 2021 | Volume: 6 | Issue: 10 | Pages: 1202

10.1001/jamacardio.2021.2833 | PMID 34185045 Get It

Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review‐based cohort study
Dymanus, Kyle , Butaney, Mohit , Magee, Diana , Hird, Amanda , Luckenbaugh, Amy N. , Merry, W. , Hall, Mary E. , Laviana, Aaron A. , Davis, Nancy B. , Klaassen, Zachary , Dymanus, Kyle A , Magee, Diana E , Hird, Amanda E , Wallis, Christopher J D , Huelster, Heather L. , Terris, Martha K.

Mayo Clinic

Cancer | June 23, 2021 | Volume: 127 | Issue: 17 | Pages: 3156-3162

10.1002/cncr.33533 | PMID 34160824 Get It

Background Ensuring representative data accrual in clinical trials is important to safeguard the generalizability of results and to minimize disparities in care. This study's goal was to evaluate differences in gender representation in trials leading to US Food and Drug Administration (FDA) cancer drug approvals. Methods An observational study was conducted from January 2014 to April 2019 using PubMed and the National Institutes of Health trials registry for primary trial reports. The National Cancer Institute's Surveillance, Epidemiology, and End Results program and US Census were consulted for national cancer incidence. The outcome was an enrollment incidence disparity (EID), which was calculated as the difference between male and female trial enrollment and national incidence, with positive values representing male overrepresentation. Results There were 149 clinical trials with 59,988 participants—60.3% and 39.7% were male and female, respectively—leading to 127 oncology drug approvals. The US incidence rates were 55.4% for men versus 44.6% for women. Gender representation varied by specific tumor type. Most notably, women were underrepresented in thyroid cancer (EID, +27.4%), whereas men were underrepresented in soft tissue cancer (EID, –26.1%). Overall, women were underrepresented when compared with expected incidence (EID, +4.9%; 42% of trials). Conclusions For many specific tumor types, women are underrepresented in clinical trials leading to FDA oncology drug approvals. It is critical to better align clinical trial cohort demographics and the populations to which these data will be extrapolated. Lay Summary This study assesses whether gender disparities exist in clinical trials leading to US Food and Drug Administration (FDA) cancer drug approvals. From January 2014 to April 2019, 149 clinical trials leading to FDA oncology drug approvals showed 60.3% and 39.7% of the enrollees were male and female, respectively. Gender representation varied by specific tumor when compared with the expected incidence rate of cancer in the United States, although women were more often underrepresented. Increased efforts are needed with regard to ensuring equitable representation in oncology clinical trials.
Rare Copy Number Variants (CNVs) and Breast Cancer Risk
Dorling, Leila , Bola, Manjeet, Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Freeman, Laura Beane, Beckmann, Matthias W. , Bojeson, Stig, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Collaborators, NBCS, Collée, J. Margriet, Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Hahen, Eric, Haiman, Christopher A. , Hoppe, Reine, Investigators, ACTB, Investigators, kConFab, Jager, Agnes , Johnson, Nichola , Keeman, Renske , Ko, Yon‐Dschun, Kosma, Veli‐Matti , Kristensen, Vessela N. , Kubelka‐Sabit, Katerina , Kurian, Alison, Larson, Nicole L. , Linet, Martha S. , Łukomska, Alicja, Mannermaa, Arto , Mavroudis, Dimitrios, Park‐Simon, Tjoung‐Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana, Sawyer, Elinor J. , Schmutzler, Rita K., Shibli, Rana , Soucy, Penny, Tomlinson, Ian , Vachon, Celine M. , Wendt, Camilla, Yang, Xiaohong R. , Easton, Douglas F. , Peterlongo, Paolo , Evans, D Gareth , Chenevix-Trench, Georgia , Sawyer, Elinor J , Dennis, Joe , Tyrer, Jonathan P. , Walker, Logan C. , Michailidou, Kyriaki , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Behrens, Sabine , Benı́tez, Javier , Bermisheva, Marina , Bojesen, Stig E. , Brenner, Hermann , Castelao, Jose E. , Clarke, Christine L. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Figueroa, Jonine D. , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García‐Closas, Montserrat , Giles, Graham G. , González‐Neira, Anna , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hoppe, Reiner , Hopper, John L. , Howell, Anthony , Jakubowska, Anna , John, Esther M. , Jones, Michael E. , Jung, Audrey , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lambrechts, Diether , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muranen, Taru , Murphy, Rachel A. , Nevanlinna, Heli , Olson, Janet E. , Olsson, Håkan , Perou, Charles M. , Pylkäs, Katri , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Smeets, Ann , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Truong, Thérèse , Vachon, Celine M. , Wendt, Camilla, Winqvist, Robert , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Simard, Jacques , Dunning, Alison M. , Pharoah, Paul D.P.

Mayo Clinic

No container title available | June 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-602209/v1 Get It

Abstract BackgroundCopy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.ResultsGene burden tests detected the strongest association for deletions in BRCA1 (P= 3.7E-18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P= 0.0008), ATM (P= 0.002) and BRCA2 (P= 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci.ConclusionsThis is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.